On the recordMay 3, 2021
Policies like referencing pricing and government price-settings will effectively turn our biopharma industry to a risk-averse, think-inside-the-box-rather-than-outside-the-box commodity industry.
Source
congress.govPolicies like referencing pricing and government price-settings will effectively turn our biopharma industry to a risk-averse, think-inside-the-box-rather-than-outside-the-box commodity industry.
McKinley warns that certain policies could harm innovation in the biopharma sector.
Share
More from David McKinley
When President Trump developed a vaccine or called for a development of vaccine, it happened within 10 months.
With all due respect, Chairman Rush--and we have been friends for years--this hearing seems to be taking on an air of distraction from what Americans are really dealing with across this country.
As Congress considers significant additional resources to boost broadband deployment and close the digital divide...